Southampton Dialysis Center is a medicare approved dialysis facility center in Franklin, Virginia and it has 14 dialysis stations. It is located in Franklin City county at 1333 Armory Dr, Franklin, VA, 23851. You can reach out to the office of Southampton Dialysis Center at (757) 562-2233. This dialysis clinic is managed and/or owned by Fresenius Medical Care. Southampton Dialysis Center has the following ownership type - Profit. It was first certified by medicare in December, 1994. The medicare id for this facility is 492576 and it accepts patients under medicare ESRD program.
| Name | Southampton Dialysis Center |
|---|---|
| Location | 1333 Armory Dr, Franklin, Virginia |
| No. of Dialysis Stations | 14 |
| Medicare ID | 492576 |
| Managed By | Fresenius Medical Care |
| Ownership Type | Profit |
| Late Shifts | No |
| 1333 Armory Dr, Franklin, Virginia, 23851 | |
| (757) 562-2233 | |
News Archive
Like the masterless samurai for whom it is named, the protein Ronin chooses an independent path, maintaining embryonic stem cells in their undifferentiated state and playing essential roles in genesis of embryos and their development, said Baylor College of Medicine researchers who reported on this novel cellular regulator in the current issue of the journal Cell.
Intellect Neurosciences, Inc., a biopharmaceutical company focused on development of disease-modifying therapeutic agents for Alzheimer's disease, announced today that it has reached a debt settlement agreement with CARBOGEN AMCIS AG, one of Intellect's largest trade creditors, in connection with prior services rendered.
CardioFocus, Inc., developer of the HeartLight Endoscopic Ablation System for the treatment of atrial fibrillation, announces that its HeartLight technology is the focus of a multicenter European clinical study for the treatment of drug-refractory persistent AF.
Immune Pharmaceuticals Inc. announced today that the first patient has been enrolled into the Phase 2 clinical trial evaluating the safety and efficacy of its first in class fully human monoclonal antibody, bertilimumab in Ulcerative Colitis (UC).
Researchers at Trinity College Dublin in collaboration with colleagues in the Department of Neurology at St Vincent's University Hospital and University College Dublin have recently reported new insights into cognitive changes in multiple sclerosis, using newly developed signal processing methods.
› Verified 9 days ago
| NPI Number | 1184728958 |
| Organization Name | Bma Southampton |
| Doing Business As | Bio-medical Applications Of Virginia, Inc. |
| Address | 1333 Armory Dr Franklin, Virginia, 23851 |
| Phone Number | (757) 562-2233 |
News Archive
Like the masterless samurai for whom it is named, the protein Ronin chooses an independent path, maintaining embryonic stem cells in their undifferentiated state and playing essential roles in genesis of embryos and their development, said Baylor College of Medicine researchers who reported on this novel cellular regulator in the current issue of the journal Cell.
Intellect Neurosciences, Inc., a biopharmaceutical company focused on development of disease-modifying therapeutic agents for Alzheimer's disease, announced today that it has reached a debt settlement agreement with CARBOGEN AMCIS AG, one of Intellect's largest trade creditors, in connection with prior services rendered.
CardioFocus, Inc., developer of the HeartLight Endoscopic Ablation System for the treatment of atrial fibrillation, announces that its HeartLight technology is the focus of a multicenter European clinical study for the treatment of drug-refractory persistent AF.
Immune Pharmaceuticals Inc. announced today that the first patient has been enrolled into the Phase 2 clinical trial evaluating the safety and efficacy of its first in class fully human monoclonal antibody, bertilimumab in Ulcerative Colitis (UC).
Researchers at Trinity College Dublin in collaboration with colleagues in the Department of Neurology at St Vincent's University Hospital and University College Dublin have recently reported new insights into cognitive changes in multiple sclerosis, using newly developed signal processing methods.
› Verified 9 days ago
| Dialysis patients with Hemoglobin data | 35 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 9 |
News Archive
Like the masterless samurai for whom it is named, the protein Ronin chooses an independent path, maintaining embryonic stem cells in their undifferentiated state and playing essential roles in genesis of embryos and their development, said Baylor College of Medicine researchers who reported on this novel cellular regulator in the current issue of the journal Cell.
Intellect Neurosciences, Inc., a biopharmaceutical company focused on development of disease-modifying therapeutic agents for Alzheimer's disease, announced today that it has reached a debt settlement agreement with CARBOGEN AMCIS AG, one of Intellect's largest trade creditors, in connection with prior services rendered.
CardioFocus, Inc., developer of the HeartLight Endoscopic Ablation System for the treatment of atrial fibrillation, announces that its HeartLight technology is the focus of a multicenter European clinical study for the treatment of drug-refractory persistent AF.
Immune Pharmaceuticals Inc. announced today that the first patient has been enrolled into the Phase 2 clinical trial evaluating the safety and efficacy of its first in class fully human monoclonal antibody, bertilimumab in Ulcerative Colitis (UC).
Researchers at Trinity College Dublin in collaboration with colleagues in the Department of Neurology at St Vincent's University Hospital and University College Dublin have recently reported new insights into cognitive changes in multiple sclerosis, using newly developed signal processing methods.
› Verified 9 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 49 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 422 |
| Percentage of adult patients getting regular hemodialysis at the center | 100 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
Like the masterless samurai for whom it is named, the protein Ronin chooses an independent path, maintaining embryonic stem cells in their undifferentiated state and playing essential roles in genesis of embryos and their development, said Baylor College of Medicine researchers who reported on this novel cellular regulator in the current issue of the journal Cell.
Intellect Neurosciences, Inc., a biopharmaceutical company focused on development of disease-modifying therapeutic agents for Alzheimer's disease, announced today that it has reached a debt settlement agreement with CARBOGEN AMCIS AG, one of Intellect's largest trade creditors, in connection with prior services rendered.
CardioFocus, Inc., developer of the HeartLight Endoscopic Ablation System for the treatment of atrial fibrillation, announces that its HeartLight technology is the focus of a multicenter European clinical study for the treatment of drug-refractory persistent AF.
Immune Pharmaceuticals Inc. announced today that the first patient has been enrolled into the Phase 2 clinical trial evaluating the safety and efficacy of its first in class fully human monoclonal antibody, bertilimumab in Ulcerative Colitis (UC).
Researchers at Trinity College Dublin in collaboration with colleagues in the Department of Neurology at St Vincent's University Hospital and University College Dublin have recently reported new insights into cognitive changes in multiple sclerosis, using newly developed signal processing methods.
› Verified 9 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Southampton Dialysis Center with elevated calcium levels.
| Patients with hypercalcemia | 51 |
| Hypercalcemia patient months | 438 |
| Hypercalcemia patients with serumcalcium greater than 10.2 mg | 1 |
| Patients with Serumphosphor | 53 |
| Patients with Serumphosphor less than 3.5 mg/dL | 11 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 25 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 24 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 23 |
| Patients with Serumphosphor greater than 7 mg/dL | 17 |
News Archive
Like the masterless samurai for whom it is named, the protein Ronin chooses an independent path, maintaining embryonic stem cells in their undifferentiated state and playing essential roles in genesis of embryos and their development, said Baylor College of Medicine researchers who reported on this novel cellular regulator in the current issue of the journal Cell.
Intellect Neurosciences, Inc., a biopharmaceutical company focused on development of disease-modifying therapeutic agents for Alzheimer's disease, announced today that it has reached a debt settlement agreement with CARBOGEN AMCIS AG, one of Intellect's largest trade creditors, in connection with prior services rendered.
CardioFocus, Inc., developer of the HeartLight Endoscopic Ablation System for the treatment of atrial fibrillation, announces that its HeartLight technology is the focus of a multicenter European clinical study for the treatment of drug-refractory persistent AF.
Immune Pharmaceuticals Inc. announced today that the first patient has been enrolled into the Phase 2 clinical trial evaluating the safety and efficacy of its first in class fully human monoclonal antibody, bertilimumab in Ulcerative Colitis (UC).
Researchers at Trinity College Dublin in collaboration with colleagues in the Department of Neurology at St Vincent's University Hospital and University College Dublin have recently reported new insights into cognitive changes in multiple sclerosis, using newly developed signal processing methods.
› Verified 9 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 49 |
| Patient months included in arterial venous fistula and catheter summaries | 407 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 65 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 6 |
News Archive
Like the masterless samurai for whom it is named, the protein Ronin chooses an independent path, maintaining embryonic stem cells in their undifferentiated state and playing essential roles in genesis of embryos and their development, said Baylor College of Medicine researchers who reported on this novel cellular regulator in the current issue of the journal Cell.
Intellect Neurosciences, Inc., a biopharmaceutical company focused on development of disease-modifying therapeutic agents for Alzheimer's disease, announced today that it has reached a debt settlement agreement with CARBOGEN AMCIS AG, one of Intellect's largest trade creditors, in connection with prior services rendered.
CardioFocus, Inc., developer of the HeartLight Endoscopic Ablation System for the treatment of atrial fibrillation, announces that its HeartLight technology is the focus of a multicenter European clinical study for the treatment of drug-refractory persistent AF.
Immune Pharmaceuticals Inc. announced today that the first patient has been enrolled into the Phase 2 clinical trial evaluating the safety and efficacy of its first in class fully human monoclonal antibody, bertilimumab in Ulcerative Colitis (UC).
Researchers at Trinity College Dublin in collaboration with colleagues in the Department of Neurology at St Vincent's University Hospital and University College Dublin have recently reported new insights into cognitive changes in multiple sclerosis, using newly developed signal processing methods.
› Verified 9 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 56 |
| Hospitalization Rate in facility | 120.5 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 229.3 |
| Hospitalization Rate: Lower Confidence Limit | 66.3 |
News Archive
Like the masterless samurai for whom it is named, the protein Ronin chooses an independent path, maintaining embryonic stem cells in their undifferentiated state and playing essential roles in genesis of embryos and their development, said Baylor College of Medicine researchers who reported on this novel cellular regulator in the current issue of the journal Cell.
Intellect Neurosciences, Inc., a biopharmaceutical company focused on development of disease-modifying therapeutic agents for Alzheimer's disease, announced today that it has reached a debt settlement agreement with CARBOGEN AMCIS AG, one of Intellect's largest trade creditors, in connection with prior services rendered.
CardioFocus, Inc., developer of the HeartLight Endoscopic Ablation System for the treatment of atrial fibrillation, announces that its HeartLight technology is the focus of a multicenter European clinical study for the treatment of drug-refractory persistent AF.
Immune Pharmaceuticals Inc. announced today that the first patient has been enrolled into the Phase 2 clinical trial evaluating the safety and efficacy of its first in class fully human monoclonal antibody, bertilimumab in Ulcerative Colitis (UC).
Researchers at Trinity College Dublin in collaboration with colleagues in the Department of Neurology at St Vincent's University Hospital and University College Dublin have recently reported new insights into cognitive changes in multiple sclerosis, using newly developed signal processing methods.
› Verified 9 days ago
The rate of readmission show you whether patients who were being treated regularly at Southampton Dialysis Center were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 20.9 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 37.2 |
| Readmission Rate: Lower Confidence Limit | 9.7 |
News Archive
Like the masterless samurai for whom it is named, the protein Ronin chooses an independent path, maintaining embryonic stem cells in their undifferentiated state and playing essential roles in genesis of embryos and their development, said Baylor College of Medicine researchers who reported on this novel cellular regulator in the current issue of the journal Cell.
Intellect Neurosciences, Inc., a biopharmaceutical company focused on development of disease-modifying therapeutic agents for Alzheimer's disease, announced today that it has reached a debt settlement agreement with CARBOGEN AMCIS AG, one of Intellect's largest trade creditors, in connection with prior services rendered.
CardioFocus, Inc., developer of the HeartLight Endoscopic Ablation System for the treatment of atrial fibrillation, announces that its HeartLight technology is the focus of a multicenter European clinical study for the treatment of drug-refractory persistent AF.
Immune Pharmaceuticals Inc. announced today that the first patient has been enrolled into the Phase 2 clinical trial evaluating the safety and efficacy of its first in class fully human monoclonal antibody, bertilimumab in Ulcerative Colitis (UC).
Researchers at Trinity College Dublin in collaboration with colleagues in the Department of Neurology at St Vincent's University Hospital and University College Dublin have recently reported new insights into cognitive changes in multiple sclerosis, using newly developed signal processing methods.
› Verified 9 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at Southampton Dialysis Center get infections in their blood each year compared to the number of infections expected for the center based on the national average.
| Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
| Infection Rate in facility | .26 (As Expected) |
| SIR: Upper Confidence Limit | 1.3 |
| SIR: Lower Confidence Limit | .01 |
News Archive
Like the masterless samurai for whom it is named, the protein Ronin chooses an independent path, maintaining embryonic stem cells in their undifferentiated state and playing essential roles in genesis of embryos and their development, said Baylor College of Medicine researchers who reported on this novel cellular regulator in the current issue of the journal Cell.
Intellect Neurosciences, Inc., a biopharmaceutical company focused on development of disease-modifying therapeutic agents for Alzheimer's disease, announced today that it has reached a debt settlement agreement with CARBOGEN AMCIS AG, one of Intellect's largest trade creditors, in connection with prior services rendered.
CardioFocus, Inc., developer of the HeartLight Endoscopic Ablation System for the treatment of atrial fibrillation, announces that its HeartLight technology is the focus of a multicenter European clinical study for the treatment of drug-refractory persistent AF.
Immune Pharmaceuticals Inc. announced today that the first patient has been enrolled into the Phase 2 clinical trial evaluating the safety and efficacy of its first in class fully human monoclonal antibody, bertilimumab in Ulcerative Colitis (UC).
Researchers at Trinity College Dublin in collaboration with colleagues in the Department of Neurology at St Vincent's University Hospital and University College Dublin have recently reported new insights into cognitive changes in multiple sclerosis, using newly developed signal processing methods.
› Verified 9 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether Southampton Dialysis Center's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
| Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
| Patients in facility's Transfusion Summary | 43 |
| Transfusion Rate in facility | 14.2 (As Expected) |
| Transfusion Rate: Upper Confidence Limit | 83 |
| Transfusion Rate: Lower Confidence Limit | 3 |
News Archive
Like the masterless samurai for whom it is named, the protein Ronin chooses an independent path, maintaining embryonic stem cells in their undifferentiated state and playing essential roles in genesis of embryos and their development, said Baylor College of Medicine researchers who reported on this novel cellular regulator in the current issue of the journal Cell.
Intellect Neurosciences, Inc., a biopharmaceutical company focused on development of disease-modifying therapeutic agents for Alzheimer's disease, announced today that it has reached a debt settlement agreement with CARBOGEN AMCIS AG, one of Intellect's largest trade creditors, in connection with prior services rendered.
CardioFocus, Inc., developer of the HeartLight Endoscopic Ablation System for the treatment of atrial fibrillation, announces that its HeartLight technology is the focus of a multicenter European clinical study for the treatment of drug-refractory persistent AF.
Immune Pharmaceuticals Inc. announced today that the first patient has been enrolled into the Phase 2 clinical trial evaluating the safety and efficacy of its first in class fully human monoclonal antibody, bertilimumab in Ulcerative Colitis (UC).
Researchers at Trinity College Dublin in collaboration with colleagues in the Department of Neurology at St Vincent's University Hospital and University College Dublin have recently reported new insights into cognitive changes in multiple sclerosis, using newly developed signal processing methods.
› Verified 9 days ago
The rate of mortality show you whether patients who were being treated regularly at Southampton Dialysis Center lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
| Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
| Patients in facility's Survival Summary | 293 |
| Mortality Rate in facility | 20.6 (As Expected) |
| Mortality Rate: Upper Confidence Limit | 27.9 |
| Mortality Rate: Lower Confidence Limit | 14.8 |
News Archive
Like the masterless samurai for whom it is named, the protein Ronin chooses an independent path, maintaining embryonic stem cells in their undifferentiated state and playing essential roles in genesis of embryos and their development, said Baylor College of Medicine researchers who reported on this novel cellular regulator in the current issue of the journal Cell.
Intellect Neurosciences, Inc., a biopharmaceutical company focused on development of disease-modifying therapeutic agents for Alzheimer's disease, announced today that it has reached a debt settlement agreement with CARBOGEN AMCIS AG, one of Intellect's largest trade creditors, in connection with prior services rendered.
CardioFocus, Inc., developer of the HeartLight Endoscopic Ablation System for the treatment of atrial fibrillation, announces that its HeartLight technology is the focus of a multicenter European clinical study for the treatment of drug-refractory persistent AF.
Immune Pharmaceuticals Inc. announced today that the first patient has been enrolled into the Phase 2 clinical trial evaluating the safety and efficacy of its first in class fully human monoclonal antibody, bertilimumab in Ulcerative Colitis (UC).
Researchers at Trinity College Dublin in collaboration with colleagues in the Department of Neurology at St Vincent's University Hospital and University College Dublin have recently reported new insights into cognitive changes in multiple sclerosis, using newly developed signal processing methods.
› Verified 9 days ago
News Archive
Like the masterless samurai for whom it is named, the protein Ronin chooses an independent path, maintaining embryonic stem cells in their undifferentiated state and playing essential roles in genesis of embryos and their development, said Baylor College of Medicine researchers who reported on this novel cellular regulator in the current issue of the journal Cell.
Intellect Neurosciences, Inc., a biopharmaceutical company focused on development of disease-modifying therapeutic agents for Alzheimer's disease, announced today that it has reached a debt settlement agreement with CARBOGEN AMCIS AG, one of Intellect's largest trade creditors, in connection with prior services rendered.
CardioFocus, Inc., developer of the HeartLight Endoscopic Ablation System for the treatment of atrial fibrillation, announces that its HeartLight technology is the focus of a multicenter European clinical study for the treatment of drug-refractory persistent AF.
Immune Pharmaceuticals Inc. announced today that the first patient has been enrolled into the Phase 2 clinical trial evaluating the safety and efficacy of its first in class fully human monoclonal antibody, bertilimumab in Ulcerative Colitis (UC).
Researchers at Trinity College Dublin in collaboration with colleagues in the Department of Neurology at St Vincent's University Hospital and University College Dublin have recently reported new insights into cognitive changes in multiple sclerosis, using newly developed signal processing methods.
› Verified 9 days ago